Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Comparative, Randomised, Adaptive Trial to Evaluate the Safety and Immunogenicity of One Dose of Comirnaty® in Subjects That Had Received One Dose of Vaxzevria®

NCT05378191 is registered in ClinicalTrials.gov with Instituto de Investigación Hospital Universitario La Paz as lead sponsor.

NCT NCT05378191
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05378191 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Comparative, Randomised, Adaptive Trial to Evaluate the Safety and Immunogenicity of One Dose of Comirnaty® in Subjects That Had Received One Dose of Vaxzevria®
Lead sponsor
Instituto de Investigación Hospital Universitario La Paz
Phase
Phase 2
Overall status
Unknown status
Start date
April 22, 2021
Completion date
December 30, 2022
Enrollment
600 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

covid19